Trial to Assess Chelation Therapy in Critical Limb Ischemia (TACT3a)

February 23, 2024 updated by: Gervasio Lamas, MD, Mt. Sinai Medical Center, Miami
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.

The study plans to enroll 50 patients with diabetes and critical limb ischemia (CLI) to prevent the major cardiovascular endpoints of major amputation, coronary revascularization, stroke, Myocardial Infarction (MI), or death (all-cause) during an average 1.25 years of follow-up. Patients will be randomly assigned to chelation or placebo with a 3:2 (30 active, 20 placebo) allocation ratio. Treatment will consist of 40 active or placebo infusions over 30 weeks. Active therapy will be the same edetate disodium-based infusion used safely and successfully in a previous published study, Trial to Assess Chelation Therapy (TACT). Baseline and post infusion urine metals will be collected. Following the final infusion, patients will be contacted quarterly until the end of the study.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 50 years
  • History of diabetes, defined as medical record evidence or patient report of currently using insulin or oral hypoglycemic agents, or with a history of fasting blood glucose measurement of 126 mg/dL or higher, or a history of HbA1c of 6.5% or higher.
  • Significant stenosis (≥ 75%) of two or more infra-popliteal arteries in the affected limb as verified by at least one imaging technique (angiography, magnetic resonance angiogram, coronary computed tomography angiogram, or doppler examination) within 6 months prior to enrollment;

  • History of CLI defined as moderate or high-risk infra-popliteal chronic critical limb ischemia (Rutherford Clinical Severity Score 4 or 5) defined as:

    • The presence of rest pain or non-healing ulceration or gangrene for at least 2 weeks plus documentation of severely compromised tissue perfusion:
    • If there is tissue loss, a resting ankle systolic pressure of ≤ 60 mmHg in the affected limb; or a resting toe systolic pressure of ≤ 40 mmHg or a tissue perfusion pressure (TPP) <40 mmHg.
    • If there is no tissue loss, a resting ankle pressure of ≤ 50 mmHg or resting toe systolic pressure of ≤ 30 mmHg or a tissue perfusion pressure (TPP) < 30 mmHg.
  • Not a candidate or a failed candidate for surgical or transcatheter revascularization;
  • Able to give informed consent.

Exclusion Criteria:

  • <7 days following lower extremity (infra-popliteal), carotid, or coronary revascularization.
  • Arterial insufficiency in the lower extremity as the result of a non-atherosclerotic disorder.
  • Subjects with evidence of active infection (e.g., cellulitis, osteomyelitis) or deep ulceration exposing bone or tendon or extensive heel ulceration
  • Subjects with extensive gangrene extending above the MT joint
  • Subjects in whom there is severe pain at rest uncontrollable with pain medications
  • Prior intravenous chelation therapy consisting of > 1 infusion within 5 years; if only 1 infusion took place, patient cannot be enrolled for at least 12 months after said infusion.
  • Oral chelation with an FDA-approved chelating agent within 2 years
  • Allergy to any components of the study drug
  • Planned leg revascularization within 1 month of enrollment
  • Symptomatic or clinically evident acute heart failure
  • Heart failure hospitalization within 3 months
  • Blood pressure >160/100
  • No venous access
  • eGFR < 30 mL/min per 1.73 m2 or lower (CKD stages 1-3) calculated with MDRD
  • Known or suspected acute kidney injury using prevalent KDIGO criteria45
  • Platelet count <100,000/mm3
  • Cigarette smoking within the last 3 months
  • Liver disease or Alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.0 times the upper limit of normal (this will require clearance by the Study PI)
  • Diseases of copper, iron, or calcium metabolism (other than osteopenia or osteoporosis, or simple iron deficiency). These require evaluation by the Study PI
  • Inability to tolerate the study-required fluid load
  • Other medical condition likely to affect patient survival within 3 years
  • Women of child-bearing potential
  • Any factor that suggests that the potential participant will not be able to adhere to the protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Active
edetate disodium (EDTA)dff active infusion
Drug: Edetate Disodium
The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
Other Names:
  • TACT EDTA infusion
Placebo Comparator: Placebo
Placebo infusion
Other: Placebo
Placebo infusions consist of 500 ml normal saline.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevention of major cardiovascular endpoints
Time Frame: 3 years (average follow-up 1.25 years)
Major cardiovascular endpoints include: coronary revascularization, stroke, MI, death (all-cause), or major amputation
3 years (average follow-up 1.25 years)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amputations
Time Frame: 3 years (average follow-up 1.25 years)
  • Major amputations due to vascular disease. Major amputations are defined as any procedure that results in amputation at the level above the ankle. 49, 50
  • Total amputations due to vascular disease
3 years (average follow-up 1.25 years)
Heart failure
Time Frame: 3 years (average follow-up 1.25 years)
• Heart failure hospitalizations or prolonged (>12 hours) ER stay for heart failure
3 years (average follow-up 1.25 years)
Changes in Pain severity
Time Frame: 3 years (average follow-up 1.25 years)
• Any changes in pain will be recorded at baseline, infusions 10, 20, 40 (or final), and end of study recorded using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference- Short Form 8a. The scale range is 1 to 5, with 1 being the best outcome (no pain interference) and 5 the worse (very much interference)
3 years (average follow-up 1.25 years)
Urine Metals
Time Frame: 1 year
• Changes in urine metal levels measured at the Metals Core Lab and measured at baseline and infusion 40 (or final).
1 year
Changes in Quality of Life
Time Frame: 3 years (average follow-up 1.25 years)
• Health-related quality of life (QOL) changes recorded at baseline, 10, 20, 40 (or final), and end of study using the 36-Item Short Form Health Survey (SF-36 v2). The 36 questions assess eight health-related concepts: physical functioning, role limitations due to physical health problems (role physical), bodily pain, general health, energy levels/fatigue (vitality), social functioning, role limitations due to emotional problems (role emotional), and psychological distress (mental health). The scales vary depending on the question asked.The survey will be used to detect change (better or worse) in participants' health state over the course of the study.
3 years (average follow-up 1.25 years)
Wound Severity
Time Frame: 3 years (average follow-up 1.25 years)
Wound severity (quantified and imaged with HIPAA-compliant photography) photographed at baseline 10, 20, 40 (or final), and end of study
3 years (average follow-up 1.25 years)
Changes in skin perfusion pressure in the ankle
Time Frame: 3 years (average follow-up 1.25 years)
• Changes in skin perfusion pressure will be measured at 10, 20, 40 (or final), and end of study, using the ankle-brachial index (mmHg)
3 years (average follow-up 1.25 years)
Changes in skin perfusion pressure in the toe
Time Frame: 3 years (average follow-up 1.25 years)
• Changes in skin perfusion pressure will be measured at 10, 20, 40 (or final), and end of study, using the toe-brachial index (mmHg).
3 years (average follow-up 1.25 years)
Changes in PAD Quality of Life
Time Frame: 3 years (average follow-up 1.25 years)
• PAD related quality of life (QOL) changes recorded at baseline, 10, 20, 40 (or final), and end of study using the Peripheral Artery Questionnaire (PAQ), which is a 20-item questionnaire measuring physical limitations, symptoms, symptom stability, treatment satisfaction, quality of life, and social function. The scales vary depending on the question asked. The survey will be used to detect change (better or worse) in participants responses over the course of the study.
3 years (average follow-up 1.25 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mt. Sinai Medical Center, Miami

Investigators

  • Principal Investigator: Gervasio Lamas, MD, Icahn School of Medicine at Mount Sinai

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 19, 2019

Primary Completion (Estimated)

July 1, 2024

Study Completion (Estimated)

July 1, 2024

Study Registration Dates

First Submitted

May 27, 2019

First Submitted That Met QC Criteria

June 9, 2019

First Posted (Actual)

June 11, 2019

Study Record Updates

Last Update Posted (Actual)

February 28, 2024

Last Update Submitted That Met QC Criteria

February 23, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 19-05-H-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

Clinical Trials on Edetate Disodium

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe